Antibacterial drugs

Pharmacokinetic interaction (decreased absorption of gemifloxacin). Gemifloxacin should be taken at least 2 hours before or 3 hours after antacids that contain aluminum or magnesium. (See Dosage and Administration: Administration.) Antacids containing calcium or calcium supplements have no clinically important pharmacokinetic interaction with gemifloxacin. Didanosine Pharmacokinetic interaction; didanosine chewable/dispersible buffered tablets, buffered powder for oral solution, or pediatric powder for oral solution prepared as an admixture with antacid may substantially decrease gemifloxacin absorption.

Gemifloxacin Mesylate: Cautions. Musculoskeletal Effects, Nervous System Effects, Sensitivity Reactions, Major Toxicities Dermatologic Reactions, Hepatic Effects, Specific Populations Pregnancy Category C. Lactation.

Adverse effects reported with ticarcillin disodium and clavulanate potassium are similar to those reported with ticarcillin alone. For information on adverse effects reported with ticarcillin and other extended-spectrum penicillins, see Cautions in the Extended-Spectrum Penicillins General Statement 8:12.16.16. Rash, pruritus, urticaria, and fever have been reported with ticarcillin disodium and clavulanate potassium.

Vials of ticarcillin disodium and clavulanate potassium labeled as containing a combined potency of 3.1 g of the drugs are reconstituted by adding approximately 13 mL of sterile water for injection or sodium chloride injection to provide a solution containing approximately 200 mg of ticarcillin per mL and 6.7 mg of clavulanic acid per mL. The vial should be shaken until the drug is dissolved.

Ticarcillin disodium and clavulanate potassium is used for the treatment of lower respiratory tract infections, skin and skin structure infections, complicated and uncomplicated urinary tract infections, bone and joint infections, septicemia, intra-abdominal infections (e.g., peritonitis), and gynecologic infections (e.g., endometritis), caused by susceptible organisms.

The drug also has been used for the treatment of anaerobic or mixed aerobic-anaerobic bacterial infections or for empiric anti-infective therapy in febrile granulocytopenic patients. For specific information on the uses of ticarcillin, seeUses in the Extended-Spectrum Penicillins General Statement 8:12.16.16. For information on the uses of ticarcillin in a fixed-ratio combination with clavulanic acid. Ticarcillin disodium is administered by slow IV injection or infusion or by deep IM injection.

Piperacillin sodium and tazobactam sodium is used parenterally for the treatment of moderate to severe infections caused by, or suspected of being caused by, susceptible b-lactamase-producing bacteria when piperacillin alone would be ineffective.

Dosage of piperacillin sodium and tazobactam sodium is expressed in terms of the total of the piperacillin and tazobactam content of the fixed combination. Potency of both piperacillin sodium and tazobactam sodium are expressed in terms of the bases of the drugs.

Oral carbenicillin indanyl sodium has been used with some success for short-term therapy or long-term suppressive therapy in the treatment of acute or chronic infections of the upper and lower urinary tract or for asymptomatic bacteriuria caused by susceptible strains of enterococci, Enterobacter, Escherichia coli, Morganella morganii, Proteus mirabilis, P. vulgaris, P. rettgeri, or Pseudomonas aeruginosa. However, most clinicians state that the drug is not a drug of choice for these infections. Some clinicians suggest that uncomplicated urinary tract infections should be treated with co-trimoxazole, fluoroquinolones, oral cephalosporins, nitrofurantoin, or fosfomycin; complicated urinary tract infections generally require parenteral therapy.